Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Retained Earnings (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Retained Earnings for 9 consecutive years, with -$960.6 million as the latest value for Q1 2026.

  • For Q1 2026, Retained Earnings fell 65647.84% year-over-year to -$960.6 million; the TTM value through Mar 2026 reached -$960.6 million, down 65647.84%, while the annual FY2025 figure was -$3.5 million, 99.49% up from the prior year.
  • Retained Earnings hit -$960.6 million in Q1 2026 for Bicycle Therapeutics, down from -$3.5 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$778000.0 in Q1 2024 and bottomed at -$960.6 million in Q1 2026.
  • Average Retained Earnings over 5 years is -$387.8 million, with a median of -$370.2 million recorded in 2023.
  • Year-over-year, Retained Earnings soared 99.79% in 2024 and then tumbled 65647.84% in 2026.
  • Bicycle Therapeutics' Retained Earnings stood at -$331.1 million in 2022, then tumbled by 54.57% to -$511.8 million in 2023, then plummeted by 33.03% to -$680.8 million in 2024, then skyrocketed by 99.49% to -$3.5 million in 2025, then tumbled by 27305.88% to -$960.6 million in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$960.6 million, -$3.5 million, and -$879.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.